ASX healthcare stocks are a popular option for investors seeking defensive assets with long-term structural growth.
These shares can offer portfolio diversification, drive high margins, and some of them have huge potential upside.
Here are three ASX healthcare stocks on my radar this week, and analysts are tipping upside well over 100% over the next 12 months.
Image source: Getty Images
Pro Medicus Ltd (ASX: PME)
The beaten-down medical imaging technology stock has dropped another 1.7% in Wednesday afternoon trade, to $125.69 a piece. The decline is part of a long string of declines off the back of sector-wide headwinds, which have seen the share price crash 62% from an all-time high recorded in mid-2025.
Sentiment didn't improve when the company posted a record-breaking half-year FY26 result in mid-February. Its revenue was up 28%, and profit jumped nearly 30%, but it still missed investors' high expectations.
But Pro Medicus has won several contracts so far in 2026, including two $40 million five-year contract renewals with its wholly owned US subsidiary, Visage Imaging, earlier this month.
I think the stock is trading well below value right now. And analysts are tipping potential for a 139% upside to $300 per share over the next 12 months.
Telix Pharmaceuticals Ltd (ASX: TLX)
Telix shares are racing higher on Wednesday, recovering some losses seen during a sharp sell-off last year.
Despite several recent headwinds, it looks like Telix shares are finally rebounding. The positive sentiment started when it filed a key regulatory approval in Europe. News of positive results from its Global Phase 3 ProstACT study last week, followed by an announcement that the company has resubmitted its New Drug Application (NDA) to the US FDA for its brain cancer imaging candidate TLX101-Px (Pixclara®), has seen investors flock to the stock.
Analysts tip the ASX healthcare stock to jump 156% to $31.59 a piece over the next 12 months.
Clarity Pharmaceuticals Ltd (ASX: CU6)
The clinical-stage radiopharmaceutical company's shares jumped higher this week on the back of good news about the development of new trial data for its prostate cancer imaging technology. The findings will be used as a basis to form a new drug submission to the FDA.
It's good news after Clarity shares suffered from volatility over the past five months, fluctuating anywhere between $5.70 and $2.73.
Analysts are excited about the prospects for growth of the ASX healthcare stock's business fundamentals and share price over the next 12 months. They have a consensus buy rating with a maximum target price of $9. That implies a potential 157% upside at the time of writing.
